HitGen Inc., a drug discovery research company, has entered into a research service agreement with Nested Therapeutics, Inc., a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis, and screening of DELs, to identify hits against targets of interest to Nested. HitGen is involved in the development of DEL technology...